- Home
- CSTL vs NXJ Comparison
CSTL vs NXJ Comparison
Compare CSTL & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- NXJ
- Stock Information
- Founded
- CSTL 2007
- NXJ 1999
- Country
- CSTL United States
- NXJ United States
- Employees
- CSTL 784
- NXJ N/A
- Industry
- CSTL Medical Specialities
- NXJ Finance/Investors Services
- Sector
- CSTL Health Care
- NXJ Finance
- Exchange
- CSTL Nasdaq
- NXJ Nasdaq
- Market Cap
- CSTL 471.5M
- NXJ 457.7M
- IPO Year
- CSTL 2019
- NXJ N/A
- Fundamental
- Price
- CSTL $16.08
- NXJ $11.14
- Analyst Decision
- CSTL Strong Buy
- NXJ
- Analyst Count
- CSTL 6
- NXJ 0
- Target Price
- CSTL $37.67
- NXJ N/A
- AVG Volume (30 Days)
- CSTL 343.8K
- NXJ 74.9K
- Earning Date
- CSTL 08-04-2025
- NXJ 01-01-0001
- Dividend Yield
- CSTL N/A
- NXJ 3.27%
- EPS Growth
- CSTL N/A
- NXJ N/A
- EPS
- CSTL N/A
- NXJ N/A
- Revenue
- CSTL $347,083,000.00
- NXJ N/A
- Revenue This Year
- CSTL N/A
- NXJ N/A
- Revenue Next Year
- CSTL $1.36
- NXJ N/A
- P/E Ratio
- CSTL N/A
- NXJ N/A
- Revenue Growth
- CSTL 38.43
- NXJ N/A
- 52 Week Low
- CSTL $15.45
- NXJ $10.06
- 52 Week High
- CSTL $35.84
- NXJ $12.24
- Technical
- Relative Strength Index (RSI)
- CSTL 32.77
- NXJ 40.09
- Support Level
- CSTL $16.00
- NXJ $11.06
- Resistance Level
- CSTL $16.65
- NXJ $11.46
- Average True Range (ATR)
- CSTL 0.77
- NXJ 0.09
- MACD
- CSTL -0.26
- NXJ -0.01
- Stochastic Oscillator
- CSTL 2.05
- NXJ 20.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About NXJ Nuveen New Jersey Qualified Municipal Fund
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.